167 related articles for article (PubMed ID: 24413638)
1. Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study.
Freedman MS; De Stefano N; Barkhof F; Polman CH; Comi G; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Lehr L; Stubinski B; Jack DL; Kappos L
J Neurol; 2014 Mar; 261(3):490-9. PubMed ID: 24413638
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
Comi G; De Stefano N; Freedman MS; Barkhof F; Uitdehaag BM; de Vos M; Marhardt K; Chen L; Issard D; Kappos L
J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):285-294. PubMed ID: 28039317
[TBL] [Abstract][Full Text] [Related]
4. Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.
Battaglini M; Vrenken H; Tappa Brocci R; Gentile G; Luchetti L; Versteeg A; Freedman MS; Uitdehaag BMJ; Kappos L; Comi G; Seitzinger A; Jack D; Sormani MP; Barkhof F; De Stefano N
Eur J Neurol; 2022 Jul; 29(7):2024-2035. PubMed ID: 35274413
[TBL] [Abstract][Full Text] [Related]
5. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP
Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.
De Stefano N; Comi G; Kappos L; Freedman MS; Polman CH; Uitdehaag BM; Hennessy B; Casset-Semanaz F; Lehr L; Stubinski B; Jack DL; Barkhof F
J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):647-53. PubMed ID: 24292999
[TBL] [Abstract][Full Text] [Related]
7. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Kappos L; Polman CH; Freedman MS; Edan G; Hartung HP; Miller DH; Montalban X; Barkhof F; Bauer L; Jakobs P; Pohl C; Sandbrink R
Neurology; 2006 Oct; 67(7):1242-9. PubMed ID: 16914693
[TBL] [Abstract][Full Text] [Related]
8. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
O'Connor P;
Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
[TBL] [Abstract][Full Text] [Related]
9. Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a.
Vrenken H; Battaglini M; de Vos ML; Nagtegaal GJ; Teixeira BCA; Seitzinger A; Jack D; Sormani MP; Uitdehaag BMJ; Versteeg A; Comi G; Kappos L; De Stefano N; Barkhof F
J Neurol; 2023 Apr; 270(4):2271-2282. PubMed ID: 36723685
[TBL] [Abstract][Full Text] [Related]
10. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 May; 18(1):68. PubMed ID: 29751787
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.
O'Connor P; Kinkel RP; Kremenchutzky M
Mult Scler; 2009 Jun; 15(6):728-34. PubMed ID: 19482863
[TBL] [Abstract][Full Text] [Related]
13. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.
Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Bauer L; Dahms S; Lanius V; Pohl C; Sandbrink R;
Lancet; 2007 Aug; 370(9585):389-97. PubMed ID: 17679016
[TBL] [Abstract][Full Text] [Related]
14. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
[TBL] [Abstract][Full Text] [Related]
15. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
[TBL] [Abstract][Full Text] [Related]
16. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
17. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
18. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
Traboulsee A; Al-Sabbagh A; Bennett R; Chang P; Li DK; ;
BMC Neurol; 2008 Apr; 8():11. PubMed ID: 18426595
[TBL] [Abstract][Full Text] [Related]
19. MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.
Nielsen JM; Pohl C; Polman CH; Barkhof F; Freedman MS; Edan G; Miller DH; Bauer L; Sandbrink R; Kappos L; Uitdehaag BM
BMC Neurol; 2009 May; 9():19. PubMed ID: 19457248
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Sanford M; Lyseng-Williamson KA
Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
